111 related articles for article (PubMed ID: 11905547)
41. Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis.
Barr RG; Bourbeau J; Camargo CA; Ram FS
Thorax; 2006 Oct; 61(10):854-62. PubMed ID: 16844726
[TBL] [Abstract][Full Text] [Related]
42. Bronchodilator effects of oxitropium bromide, fenoterol, and their combination in normal subjects.
Fujimura M; Kamio Y; Matsuda T; Hashimoto T
Clin Auton Res; 1993 Feb; 3(1):31-5. PubMed ID: 8477178
[TBL] [Abstract][Full Text] [Related]
43. Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial.
Tashkin DP
Expert Rev Respir Med; 2010 Jun; 4(3):279-89. PubMed ID: 20524910
[TBL] [Abstract][Full Text] [Related]
44. Incremental benefit of adding oxitropium bromide to formoterol in patients with stable COPD.
Cazzola M; Di Perna F; Califano C; Vinciguerra A; D'Amato M
Pulm Pharmacol Ther; 1999; 12(4):267-71. PubMed ID: 10501652
[TBL] [Abstract][Full Text] [Related]
45. A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD.
Cazzola M; Santus P; Matera MG; Carlucci P; Belloli E; Di Marco F; Centanni S
Respir Med; 2003 May; 97(5):458-62. PubMed ID: 12735660
[TBL] [Abstract][Full Text] [Related]
46. Double-blind randomized parallel group study comparing the efficacy and safety of tiotropium and ipratropium in the treatment of COPD patients in Taiwan.
Hsu JY; Perng RP; Lu JY; Wu CP; Huang MS; Luh KT; Yang PC
J Formos Med Assoc; 2006 Sep; 105(9):708-14. PubMed ID: 16959618
[TBL] [Abstract][Full Text] [Related]
47. Oxygen desaturation and breathlessness during corridor walking in chronic obstructive pulmonary disease: effect of oxitropium bromide.
Spence DP; Hay JG; Carter J; Pearson MG; Calverley PM
Thorax; 1993 Nov; 48(11):1145-50. PubMed ID: 8296259
[TBL] [Abstract][Full Text] [Related]
48. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease.
Calverley PM; Lee A; Towse L; van Noord J; Witek TJ; Kelsen S
Thorax; 2003 Oct; 58(10):855-60. PubMed ID: 14514937
[TBL] [Abstract][Full Text] [Related]
49. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial.
Troosters T; Celli B; Lystig T; Kesten S; Mehra S; Tashkin DP; Decramer M;
Eur Respir J; 2010 Jul; 36(1):65-73. PubMed ID: 20185426
[TBL] [Abstract][Full Text] [Related]
50. Improved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist Inhaler in patients with COPD.
Kilfeather SA; Ponitz HH; Beck E; Schmidt P; Lee A; Bowen I; Hesse Ch
Respir Med; 2004 May; 98(5):387-97. PubMed ID: 15139567
[TBL] [Abstract][Full Text] [Related]
51. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
52. [Effects of aerosol oxitropium bromide and fenoterol on maximal exercise capacity in chronic obstructive pulmonary disease and their correlation with air flow during exercise and with parameters of maximal exercise].
Suruda T; Nakamura H; Kobayashi H; Uetani K; Nishio M; Higashimoto Y; Funasako M; Ohata M
Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Sep; 31(9):1089-95. PubMed ID: 8255017
[TBL] [Abstract][Full Text] [Related]
53. Bronchodilator efficacy of tiotropium-formoterol via single pressurized meter dose inhaler (pMDI) versus tiotropium alone in COPD.
Salvi S; Brashier B; Gothi D; Karkhanis V; Madas S; Gogtay J; Joshi J
Pulm Pharmacol Ther; 2014 Feb; 27(1):90-5. PubMed ID: 23752057
[TBL] [Abstract][Full Text] [Related]
54. A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium.
Anzueto A; Niewoehner DE; Leimer I; Rühmkorf F; Celli BR; Decramer M; Tashkin DP
Respir Med; 2013 Dec; 107(12):1912-22. PubMed ID: 23969305
[TBL] [Abstract][Full Text] [Related]
55. Uplifting times for COPD.
Halpin DM
Prim Care Respir J; 2008 Dec; 17(4):197-8. PubMed ID: 18972060
[No Abstract] [Full Text] [Related]
56. Effect of a single exacerbation on decline in lung function in COPD.
Halpin DMG; Decramer M; Celli BR; Mueller A; Metzdorf N; Tashkin DP
Respir Med; 2017 Jul; 128():85-91. PubMed ID: 28610675
[TBL] [Abstract][Full Text] [Related]
57. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.
Brusasco V; Hodder R; Miravitlles M; Korducki L; Towse L; Kesten S
Thorax; 2003 May; 58(5):399-404. PubMed ID: 12728159
[TBL] [Abstract][Full Text] [Related]
58. Short term effect of a single dose of formoterol or tiotropium on the isolated nocturnal hypoxemia in stable COPD patients: a double blind randomized study.
Sposato B; Franco C
Eur Rev Med Pharmacol Sci; 2008; 12(3):203-11. PubMed ID: 18700693
[TBL] [Abstract][Full Text] [Related]
59. Comparison of the bronchodilator activities of oxitropium bromide, fenoterol, and their combination in patients with chronic obstructive pulmonary disease and bronchial asthma.
Nishi K; Fujimura M; Myou S; Ooka T; Sakamoto S; Saitou M; Kasahara K; Matsuda T
Clin Auton Res; 1993 Feb; 3(1):41-4. PubMed ID: 8477180
[TBL] [Abstract][Full Text] [Related]
60. Effects of inhaled oxitropium and fenoterol, alone and in combination, in chronic airflow obstruction.
Frith PA; Jenner B; Atkinson J
Respiration; 1986; 50 Suppl 2():294-7. PubMed ID: 3563116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
